Skip to content
The Classy Investors
  • Business
  • Stock
  • Politics
  • 100 Years of the Stock Market
Subscribe
The Classy Investors
  • Business
  • Stock
  • Politics
  • 100 Years of the Stock Market
Menu
  • Business
  • Stock
  • Politics
  • 100 Years of the Stock Market
Business

Wellness Giant Bets Big on Biohacking Despite Scientific Gray Areas

November 19, 2026 • 2 min read

Hims and Hers is expanding its footprint into the world of biohacking with the launch of its Peptides plus platform, offering five different compounded formulations designed for everything from muscle recovery to anti aging. The move comes amid a surge in popularity for these short chains of amino acids among fitness enthusiasts seeking an edge in performance and longevity. However, the company paired its ambitious rollout with a candid admission that it still has much to learn regarding the optimal usage and overall effectiveness of these treatments.

None of the new offerings have received official approval from the Food and Drug Administration, though the company maintains they are legally authorized and produced by licensed pharmacies following strict quality standards. The current lineup includes substances like sermorelin and NAD plus, alongside vitamin B 12 and L carnitine. Looking ahead, the brand plans to introduce further unapproved peptides such as BPC 157 and TB 500, despite the fact that much of the existing research on those specific compounds has been limited to animal studies rather than human trials.

To manage the risks associated with these unregulated treatments, Hims says customers must first undergo a health assessment with a licensed provider to create a personalized plan. Chief Medical Officer Dr. Anant Vinjamoori acknowledged that the industry lacks the traditional volume of data usually required for such compounds but suggested that a company of their scale has a responsibility to lead the way in gathering that information. This perspective is echoed by board member Andrew Huberman, who views these treatments as legitimate medicine rather than mere trends when backed by physician oversight.

Not everyone is convinced that telehealth is the right venue for these experiments. Some academic experts warn that relying on anecdotal success stories instead of rigorous clinical trials is dangerous, noting that without standardized testing, proper dosing remains largely guesswork. Critics argue that introducing synthetic peptides into the body without deep scientific backing could trigger adverse immune responses or unforeseen long term complications, leaving patients in a regulatory gray area where safety profiles remain unknown.

Share
Previous Claude Creator Prepares For Historic Market Debut Amid Massive Investor Frenzy
Next Wall Street Holds Its Breath for Anthropic Debut Amid AI Cooling Period

Related stories

Business

Internal Tension Simmers at Nvidia as New Leadership Attempts to Steady the Ship

November 19, 2026
Business

Hawkish Shift At The Fed As Waller Calls For Aggressive Inflation Shock

November 19, 2026
Business

Claude Creator Prepares For Historic Market Debut Amid Massive Investor Frenzy

November 19, 2026

Political Control Over Time

Past performance doesn't guarantee future results. Market returns affected by multiple factors.

The Daily Brief

[pages_company_name]1395 Brickell Ave
Miami, Florida, 33131, United States
Email: info@buzzburst.net

Categories

  • Business 120
  • Stock 120
  • Politics 120

Updated pre-market, daily

[pages_company_name]1395 Brickell Ave
Miami, Florida, 33131, United States
Email: info@buzzburst.net
The Classy Investors

Useful Links

Terms and ConditionsPrivacy Policy

Categories

Business Stock Politics

Loading…

Copyright © 2026 theclassyinvestors.com | All Rights Reserved

Newsletter

Get the brief in your inbox

[pages_company_name]1395 Brickell Ave
Miami, Florida, 33131, United States
Email: info@buzzburst.net